Literature DB >> 33515326

High ECG Risk-Scores Predict Late Gadolinium Enhancement on Magnetic Resonance Imaging in HCM in the Young.

Anna Wålinder Österberg1, Ingegerd Östman-Smith2, Robert Jablonowski3, Marcus Carlsson3, Henrik Green4,5, Cecilia Gunnarsson6, Petru Liuba7, Eva Fernlund8,9.   

Abstract

An ECG risk-score has been described that predicts high risk of subsequent cardiac arrest in young patients with hypertrophic cardiomyopathy (HCM). Myocardial fibrosis measured by cardiac magnetic resonance (CMR) late gadolinium enhancement (LGE) also affects prognosis. We assessed whether an ECG risk-score could be used as an indicator of myocardial fibrosis or perfusion deficit on CMR in HCM. In total 42 individuals (7-31 years); 26 HCM patients, seven genotype-positive, phenotype-negative individuals at risk of HCM (first-degree relatives) and nine healthy volunteers, underwent CMR to identify, and grade extent of, myocardial fibrosis and perfusion defect. 12-lead ECG was used for calculating the ECG risk-score (grading 0-14p). High-risk ECG (risk-score > 5p) occurred only in the HCM group (9/26), and the proportion was significantly higher vs mutation carriers combined with healthy volunteers (0/16, p = 0.008). Extent of LGE correlated to the ECG-score (R2 = 0.47, p = 0.001) in sarcomeric mutations. In low-risk ECG-score patients (0-2p), median percent of myocardium showing LGE (LGE%LVM) were: 0% [interquartile range, IQR, 0-0%], in intermediate-risk (3-5p): 5.4% [IQR 0-13.5%] and in high-risk (6-14p): 10.9% [IQR 4.2-12.3%]. ECG-score > 2p had a sensitivity and specificity of 79% and 84% to detect positive LGE on CMR and 77% vs. 75% to detect perfusion defects in sarcomeric mutations carriers. In patients with myocardial fibrosis as identified by LGE, median ECG risk-score was 8p [range 3-10p]. In conclusions, ECG risk-score > 2 p could be used as a cut-off for screening of myocardial fibrosis. Thus ECG risk-score is an inexpensive complementary tool in risk stratification of HCM in the young.

Entities:  

Keywords:  CMR; ECG risk-score; HCM; Myocardial fibrosis; Myocardial perfusion defect

Mesh:

Substances:

Year:  2021        PMID: 33515326     DOI: 10.1007/s00246-020-02506-9

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  21 in total

Review 1.  Hypertrophic cardiomyopathy in children.

Authors:  Jeffrey P Moak; Juan Pablo Kaski
Journal:  Heart       Date:  2012-05-16       Impact factor: 5.994

2.  A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).

Authors:  Constantinos O'Mahony; Fatima Jichi; Menelaos Pavlou; Lorenzo Monserrat; Aristides Anastasakis; Claudio Rapezzi; Elena Biagini; Juan Ramon Gimeno; Giuseppe Limongelli; William J McKenna; Rumana Z Omar; Perry M Elliott
Journal:  Eur Heart J       Date:  2013-10-14       Impact factor: 29.983

Review 3.  Hypertrophic cardiomyopathy.

Authors:  Barry J Maron; Martin S Maron
Journal:  Lancet       Date:  2012-08-06       Impact factor: 79.321

4.  Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids).

Authors:  Gabrielle Norrish; Tao Ding; Ella Field; Lidia Ziólkowska; Iacopo Olivotto; Giuseppe Limongelli; Aristides Anastasakis; Robert Weintraub; Elena Biagini; Luca Ragni; Terence Prendiville; Sophie Duignan; Karen McLeod; Maria Ilina; Adrián Fernández; Regina Bökenkamp; Anwar Baban; Peter Kubuš; Piers E F Daubeney; Georgia Sarquella-Brugada; Sergi Cesar; Chiara Marrone; Vinay Bhole; Constancio Medrano; Orhan Uzun; Elspeth Brown; Ferran Gran; Francisco J Castro; Graham Stuart; Gabriele Vignati; Roberto Barriales-Villa; Luis G Guereta; Satish Adwani; Katie Linter; Tara Bharucha; Pablo Garcia-Pavia; Torsten B Rasmussen; Margherita M Calcagnino; Caroline B Jones; Hans De Wilde; J Toru-Kubo; Tiziana Felice; Jens Mogensen; Sujeev Mathur; Zdenka Reinhardt; Constantinos O'Mahony; Perry M Elliott; Rumana Z Omar; Juan P Kaski
Journal:  JAMA Cardiol       Date:  2019-09-01       Impact factor: 14.676

5.  Young patients with hypertrophic cardiomyopathy, but not subjects at risk, show decreased myocardial perfusion reserve quantified with CMR.

Authors:  Tom Gyllenhammar; Eva Fernlund; Robert Jablonowski; Jonas Jögi; Henrik Engblom; Petru Liuba; Håkan Arheden; Marcus Carlsson
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-08-19       Impact factor: 6.875

6.  Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia.

Authors:  C Basso; G Thiene; D Corrado; G Buja; P Melacini; A Nava
Journal:  Hum Pathol       Date:  2000-08       Impact factor: 3.466

7.  Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease.

Authors:  A M Varnava; P M Elliott; S Sharma; W J McKenna; M J Davies
Journal:  Heart       Date:  2000-11       Impact factor: 5.994

8.  Electrocardiographic amplitudes: a new risk factor for sudden death in hypertrophic cardiomyopathy.

Authors:  Ingegerd Ostman-Smith; Aase Wisten; Eva Nylander; Ewa-Lena Bratt; Anne de-Wahl Granelli; Abderrahim Oulhaj; Erik Ljungström
Journal:  Eur Heart J       Date:  2009-11-05       Impact factor: 29.983

9.  Predictors of risk for sudden death in childhood hypertrophic cardiomyopathy: the importance of the ECG risk score.

Authors:  Ingegerd Östman-Smith; Gunnar Sjöberg; Annika Rydberg; Per Larsson; Eva Fernlund
Journal:  Open Heart       Date:  2017-10-21

10.  Inline perfusion mapping provides insights into the disease mechanism in hypertrophic cardiomyopathy.

Authors:  Claudia Camaioni; Kristopher D Knott; Joao B Augusto; Andreas Seraphim; Stefania Rosmini; Fabrizio Ricci; Redha Boubertakh; Hui Xue; Rebecca Hughes; Gaby Captur; Luis Rocha Lopes; Louise Anne Elizabeth Brown; Charlotte Manisty; Steffen Erhard Petersen; Sven Plein; Peter Kellman; Saidi A Mohiddin; James C Moon
Journal:  Heart       Date:  2019-12-10       Impact factor: 5.994

View more
  4 in total

1.  Comprehensive Proteomics Profiling Identifies Patients With Late Gadolinium Enhancement on Cardiac Magnetic Resonance Imaging in the Hypertrophic Cardiomyopathy Population.

Authors:  Bradley S Lander; Yanling Zhao; Kohei Hasegawa; Mathew S Maurer; Albree Tower-Rader; Michael A Fifer; Muredach P Reilly; Yuichi J Shimada
Journal:  Front Cardiovasc Med       Date:  2022-06-17

Review 2.  What Aspects of Phenotype Determine Risk for Sudden Cardiac Death in Pediatric Hypertrophic Cardiomyopathy?

Authors:  Ingegerd Östman-Smith
Journal:  J Cardiovasc Dev Dis       Date:  2022-04-21

3.  Association of QTc Interval and V4-S Wave With Appropriate ICD Therapy in Hypertrophic Cardiomyopathy.

Authors:  Nixiao Zhang; Sijing Cheng; Hongxia Niu; Min Gu; Hui Peng; Zhijun Sun; Xi Liu; Yu Deng; Xuhua Chen; Wei Hua
Journal:  Front Cardiovasc Med       Date:  2022-05-12

4.  Pediatric Hypertrophic Cardiomyopathy: Exploring the Genotype-Phenotype Association.

Authors:  Minh B Nguyen; Seema Mital; Luc Mertens; Aamir Jeewa; Mark K Friedberg; Julien Aguet; Arnon Adler; Christopher Z Lam; Andreea Dragulescu; Harry Rakowski; Olivier Villemain
Journal:  J Am Heart Assoc       Date:  2022-02-18       Impact factor: 6.106

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.